“ Claudio Soto, general manager of PAREXEL Mexico, discusses how the clinical research process required to receive approval for a new clinical protocol in Mexico is fairly… ”
In Conversation
“ The managing partner of a specialist boutique PR and integrated communications management agency serving the local pharma sector unveils his theory of holistic, industry-wide lobbying and… ”
“ The general manager of a British pharma giant with over 25 years of presence in Romania discusses how vaccination programs can play a significant role in… ”
“ The directors of one of the leading in country contract research organisations, explain exactly what makes Romania such an attractive destination for clinical trials. They also… ”
“ The directors of one of the leading in country contract research organisations, explain exactly what makes Romania such an attractive destination for clinical trials. They also… ”
“ The general manager of one of the leading CROs in Romania explains how the country in gathering pace as a top tier clinical trials destination country… ”
“ The country manager of one of the foremost providers of sustainable and integrated healthcare solutions describes the sorts of local adaptations that need to be enacted when launching… ”
“ One of the directors of Romania's number one producer of suppositories and the only in-country manufacturer of contraceptive ovules speaks out about how the country is fast becoming… ”
“ The American Chamber of Commerce’s executive director in Thailand explains the chamber’s role in facilitating mutually beneficial relations between American businesses and Thailand, the challenges and… ”
“ BMS is actively working towards positioning Thailand as the regional hub due to its strategic location and good talent pool of entrepreneurial mindset. Overall, we see… ”
“ The president of the Turkish Drug and Medical Device Agency (TITCK) discusses new initiatives and reforms being carried out by his agency, including its work towards becoming… ”
“ The CEO of Centurion shares his ambitious vision for the company's expansion into plasma products, biotech, orphan drugs, and generic injectables over the coming years, while simultaneously developing… ”
